2025-12-21 - Analysis Report
Okay, let's break down the information provided about Eli Lilly and Co. (LLY).

**0) Overview:**

*   **Eli Lilly and Co. Overview:** A pharmaceutical company focused on discovering, developing, and marketing medicines.

**1) Return Rate Comparison:**

*   **LLY Cumulative Return:** 305.60%
*   **VOO (S&P 500) Cumulative Return:** 100.88%
*   **Divergence:**
    *   **Current:** 199.3
    *   **Relative Divergence:** 82.6

*   **Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the period examined. The current divergence is substantial (199.3) and the relative divergence of 82.6 indicates that the outperformance is near the upper end of its historical range relative to the S&P 500.

    *   **Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha  | Beta  | Cap(B) |
|------------|---------|--------|--------|-------|--------|
| 2015-2017  | 11.0%   | 76.1%  | -17.0% | -0.0  | 75.7   |
| 2016-2018  | 39.0%   | 68.9%  | 24.0%  | -0.0  | 103.7  |
| 2017-2019  | 41.0%   | 68.9%  | 19.0%  | 0.4   | 117.8  |
| 2018-2020  | 34.0%   | 79.8%  | 10.0%  | 0.4   | 151.4  |
| 2019-2021  | 53.0%   | 79.8%  | 7.0%   | 0.5   | 247.6  |
| 2020-2022  | 64.0%   | 79.8%  | 65.0%  | 0.4   | 328.0  |
| 2021-2023  | 125.0%  | 78.9%  | 124.0% | 0.2   | 522.6  |
| 2022-2024  | 134.0%  | 81.2%  | 113.0% | 0.2   | 692.1  |
| 2023-2025  | 197.0%  | 83.5%  | 132.0% | 0.2   | 960.5  |

    *   **CAGR:**  The Compounded Annual Growth Rate is increasing substantially over the years. Recent figures show very strong growth.
    *   **MDD:**  Maximum Drawdown is relatively high. This indicates that the stock price has seen significant drops from peak to trough during these periods. Investors should be aware of this volatility.
    *   **Alpha:** The Alpha is generally positive and very high in recent years, especially between 2020 and 2025, reflecting strong risk-adjusted outperformance compared to the market.
    *   **Beta:** The Beta values are low, and even negative in the early periods. A beta near zero suggests LLY's price movements are largely independent of the overall market (S&P 500). The beta has increased in recent years but remains low.
    *   **Cap(B):** Market capitalization has grown dramatically.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 1071.43994140625
*   **Last-market Price:** 1071.44
*   **Last-market Previous Close:** 1056.88
*   **Last-market Change:** 1.38%
*   **5-day SMA:** 1057.318
*   **20-day SMA:** 1042.5557
*   **60-day SMA:** 931.1742

*   **Analysis:** The stock is trading above its 5-day, 20-day, and 60-day Simple Moving Averages (SMAs). This suggests an upward trend in the short, medium and long term. The close is a bit higher than the 5-day and 20-day SMA, indicating the recent growth.

**3) Index Indicators:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment Recommended)
*   **RSI:** 55.59
*   **PPO:** -0.23
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent (20 days) relative divergence change:** 10.1 (+) (단기상승 - short-term rise)
*   **Expected Return (%):** 51.6%

*   **Analysis:**
    *   **MRI:** A Medium Investment recommendation indicates a reasonable level of risk for potential investors.
    *   **RSI:** An RSI of 55.59 is in neutral territory, suggesting the stock is neither overbought nor oversold.
    *   **PPO:** The PPO is negative but close to zero, suggesting that short-term momentum is slightly weaker than long-term momentum, but not significantly so.
    *   **Hybrid Signal:** Suggests a strong buy signal, with MRI of 0.90, reinforcing the bullish outlook.
    *   **Divergence Change:** The recent increase in relative divergence (10.1%) indicates a short-term upward trend in LLY's outperformance.
    *   **Expected Return:** A high expected return (51.6%) suggests that analysts anticipate continued strong performance.
    *   **Price change:** The recent change of 1.38% shows there is a volatility, which should be considered.

**4) Recent News & Significant Events:**

*   **Key Themes:**
    *   **Stock Price Performance:** Multiple articles highlight recent stock price increases (e.g., "LLY stock rose 4% this week").
    *   **Weight-Loss Drugs:** Eli Lilly's weight-loss medications (Zepbound, Orforglipron pill) are a central focus, with discussions on pricing and clinical data.
    *   **Analyst Outlook:** The articles touch on analyst opinions and future forecasts for the company.
    *   **Institutional Investment:** Reports of Whalen Wealth Management Inc. purchasing shares indicate positive sentiment from institutional investors.
    *   **$1 Trillion Drugmaker:** Highlighting the size and influence of Eli Lilly in the pharmaceutical market.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean of 1.70)
*   **Target Price:** Average target of $1093.22, with a high of $1500.00 and a low of $770.00.

*   **Analysis:** The analyst consensus is strongly bullish, with a "Buy" rating. The average target price suggests further upside potential from the current price of $1071.44. The high target price indicates some analysts are particularly optimistic. Recent Rating changes are not provided in your prompt.

**5) Recent Earnings Analysis:**

| 날짜        | EPS   | 매출        |
|-------------|-------|-------------|
| 2025-10-30  | 6.22  | 17.60 B$   |
| 2025-08-07  | 6.3   | 15.56 B$   |
| 2025-05-01  | 3.07  | 12.73 B$   |
| 2024-10-30  | 1.08  | 11.44 B$   |
| 2025-10-30  | 1.08  | 11.44 B$   |

*   **Analysis:**
    *   **EPS:** Earnings per share (EPS) has shown very strong growth from 2024 to 2025.
    *   **Revenue:** Revenue has also increased significantly over the past year. The trend indicates substantial growth in both profitability and sales.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.60B    | 82.91%        |
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE     |
|--------------|------------|---------|
| 2025-09-30   | $23.79B    | 23.46%  |
| 2025-06-30   | $18.27B    | 30.98%  |
| 2025-03-31   | $15.76B    | 17.50%  |
| 2024-12-31   | $14.19B    | 31.07%  |
| 2024-09-30   | $14.24B    | 6.81%   |

*   **Analysis:**
    *   **Revenue:** Revenue has steadily increased over the quarters.
    *   **Profit Margin:** Profit margins are consistently high (above 80%), indicating strong profitability and efficient operations.
    *   **Equity:** Equity has grown significantly over the period.
    *   **ROE:** Return on Equity (ROE) fluctuates but remains generally strong, reflecting the company's ability to generate profits from shareholders' investments.

**7) Comprehensive Analysis:**

Eli Lilly and Co. (LLY) demonstrates very strong financial performance and positive market sentiment.

*   **Outperformance:** LLY has significantly outperformed the S&P 500, and the relative divergence suggests this outperformance is near its historical peak.
*   **Growth:** The company is exhibiting robust revenue and earnings growth, driven in part by its weight-loss medications. This is confirmed by both recent earnings data and revenue/profitability data.
*   **Profitability:** Consistently high profit margins and strong ROE indicate efficient operations and effective capital management.
*   **Analyst Sentiment:** Analysts have a very positive outlook, with a consensus "Buy" rating and a target price suggesting further upside.
*   **Market Risk:** The MRI is at 0.7, which indicates a "Medium Investment" opportunity. Also, the Hybrid signal also indicated a very safe investment opportunity.
*   **Volatility:** Investors should note that despite the positive outlook, the stock has experienced significant maximum drawdowns historically. Recent volatility is reflected with price changes.

**In conclusion, Eli Lilly is a company showing strong growth and profitability, with a positive outlook from analysts. While the price is high, the expected return on investment seems very favorable.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.